Drug Profile
Research programme: cancer therapeutic companion diagnostics - Merck KGaA/Roche Tissue Diagnostics
Latest Information Update: 13 Jul 2021
Price :
$50
*
At a glance
- Originator Ventana Medical Systems
- Developer Roche Tissue Diagnostics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 13 Jul 2021 Ventana Medical Systems is now called Roche Tissue Diagnostics
- 28 Aug 2018 No recent reports of development identified for research development in Cancer(Diagnosis) in USA
- 10 Jul 2014 Early research in Cancer (diagnosis) in USA (unspecified route)